Navigation Links
BioSpecifics Technologies Corp. to Present at the Aegis Capital 2013 Healthcare Conference
Date:9/19/2013

LYNBROOK, N.Y., Sept. 19, 2013 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first-in-class collagenase-based products marketed as XIAFLEX® in the U.S and XIAPEX® in the EU, today announced that BioSpecifics' President, Tom Wegman, will present a corporate overview at the Aegis Capital 2013 Healthcare Conference.

The presentation will take place on Thursday, September 26, 2013 at 4:00 p.m. EDT (1:00 p.m. PDT) at the Encore at Wynn hotel in Las Vegas, NV. This event will not be webcast.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications to date. Injectable collagenase is currently marketed as XIAFLEX® (collagenase clostridium histolyticum (CCH)) in the U.S. for the treatment of adult Dupuytren's contracture patients with a palpable cord in the palm by BioSpecifics' partner, Auxilium Pharmaceuticals, Inc. (Auxilium) and marketed in Europe and approved in Canada. Swedish Orphan Biovitrum AB has marketing rights for XIAPEX® (the EU tradename for CCH) for the treatment of Dupuytren's contracture and Peyronie's disease in 71 Eurasian and African countries. Asahi Kasei Pharma Corporation has development and commercialization rights for XIAFLEX for the treatment of Dupuytren's contracture and Peyronie's disease in Japan and Actelion Pharmaceuticals Ltd. has development and commercialization rights for XIAFLEX for these two indications in Canada, Mexico, Brazil and Australia'/>"/>

SOURCE BioSpecifics Technologies Corp.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. BioSpecifics Technologies Corp. to Present at the Stifel Nicolaus 2013 Healthcare Conference
2. BioSpecifics Technologies Corp. Reports Second Quarter 2013 Financial Results
3. BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2013 Financial Results on Thursday, August 8, 2013
4. BioSpecifics Technologies Corp. to Present at Jefferies 2013 Global Healthcare Conference
5. BioSpecifics Technologies Corp. to Host Conference Call to Report First Quarter 2013 Financial Results on Friday, May 10, 2013
6. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2012 Financial Results
7. BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2012 Financial Results on Tuesday, March 12, 2013
8. BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor Conferences
9. BioSpecifics Technologies Corp. to Webcast, Live, at RetailInvestorConferences.com on December 6th
10. BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2012 Financial Results on November 8, 2012
11. BioSpecifics Technologies Corp. to Present at Two Upcoming Investor Conferences in September
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Calif. , Aug. 31, 2015  Regulatory ... and government, where regulations are often strict and ... is driving a demand for professionals who have ... these regulations across a product lifecycle and demonstrate ... The University of California, Irvine Extension , ...
(Date:8/31/2015)... , August 31, 2015 ... (TASE: BOLT, OTCQX: BLGTY) ("BioLight" or the "Company"), ... biomedical innovations in ophthalmology and cancer diagnostics, today ... (TASE: MCTC), has identified several new genetic markers ... jawbone in patients treated with bisphosphonate drugs and ...
(Date:8/31/2015)... Premune and Innovet ... licensing agreement for Redonyl ® Ultra. The product, ... veterinary dermatology market, is a nutritional supplement based on ... in dogs and cats. Redonyl ® Ultra is ... has been received positively in the country by veterinarians ...
Breaking Medicine Technology:UC Irvine Extension Launches New Regulatory Affairs and Compliance Certificate Program 2UC Irvine Extension Launches New Regulatory Affairs and Compliance Certificate Program 3BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 2BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 3BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 4Premune Broadens Portfolio With Novel Innovet Skin Health Product 2Premune Broadens Portfolio With Novel Innovet Skin Health Product 3Premune Broadens Portfolio With Novel Innovet Skin Health Product 4
... Plus, Higher then Expected MCI Prevalence Shows Urgent ... Two studies related to,experimental Alzheimer,s therapies reported ... Conference on Alzheimer,s,Disease (ICAD 2008) in Chicago., ... AL-108, targeted early,abnormal brain changes in a protein ...
... July 28 Cardium Therapeutics,(Amex: CXM ) ... as Chief,Medical Officer to lead the Company,s late-stage ... the MATRIX Phase 2b,clinical study that is evaluating ... ulcers, and the AWARE Phase 3 clinical study ...
Cached Medicine Technology:Two New Alzheimer's Disease Studies Show Advances Against Different Treatment Targets 2Two New Alzheimer's Disease Studies Show Advances Against Different Treatment Targets 3Two New Alzheimer's Disease Studies Show Advances Against Different Treatment Targets 4Two New Alzheimer's Disease Studies Show Advances Against Different Treatment Targets 5Two New Alzheimer's Disease Studies Show Advances Against Different Treatment Targets 6Cardium Announces Appointment of Paul A. Foster, M.D. to Lead Generx and Excellarate Late-Stage Development Activities 2Cardium Announces Appointment of Paul A. Foster, M.D. to Lead Generx and Excellarate Late-Stage Development Activities 3Cardium Announces Appointment of Paul A. Foster, M.D. to Lead Generx and Excellarate Late-Stage Development Activities 4Cardium Announces Appointment of Paul A. Foster, M.D. to Lead Generx and Excellarate Late-Stage Development Activities 5
(Date:8/31/2015)... ... August 31, 2015 , ... ... may be at a greater risk for injury, potentially because they are more ... of Pittsburgh Graduate School of Public Health analysis discovered. , The research, ...
(Date:8/31/2015)... York, NY (PRWEB) , ... August 31, 2015 ... ... simulations that enable users to develop skills and assess their competencies in managing ... of research, will present at the Defense Centers of Excellence for Psychological ...
(Date:8/31/2015)... IL (PRWEB) , ... August 31, 2015 , ... On ... With A Mission” at the Adams County Fairgrounds in Mendon, IL. The purpose behind ... school districts of Mendon and neighboring town, Quincy. Best Drug Rehabilitation’s sponsorship of “Music ...
(Date:8/31/2015)... ... August 31, 2015 , ... The German soccer league (DFL ... (CMS) and make website updates quicker and more flexible. The company's CMS solution ... Bundesliga (the German equivalent of the U.S. Soccer Federation) more modern, exciting and ...
(Date:8/31/2015)... ... ... “My mother and husband use oxygen therapy and the tubing irritates the ... be a comfortable way to prevent the irritation, so I invented this.” She invented ... secure way to anchor the cannula tubing used in oxygen therapy and it prevents ...
Breaking Medicine News(10 mins):Health News:Television Viewing Linked to Higher Injury Risk in Hostile People 2Health News:Television Viewing Linked to Higher Injury Risk in Hostile People 3Health News:Kognito’s Glenn Albright to Present at DCoE Summit 2Health News:2015 "Music With A Mission" Sponsor Best Drug Rehabilitation Releases Artist Compilation Video 2Health News:2015 "Music With A Mission" Sponsor Best Drug Rehabilitation Releases Artist Compilation Video 3Health News:On the Ball with FirstSpirit: German Soccer League (DFL Digital Sports) Opts for e-Spirit’s CMS 2Health News:InventHelp® Inventor Designs Nasal Cannula Ear Protector (AVZ-1217) 2
... Recent research has revealed that women aged 60 and ... heart attack compared to others. The results of the ... such patients when compared to heart attack patients who ... been published in the April 24 issue of the ...
... Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, ... Shipments of pravastatin sodium tablets// have been started ... mg strengths. ,Watson Pharmaceuticals, Inc. has ... leading specialty pharmaceutical company that specializes in the ...
... Pyszczynski, professor, Psychology, University of Colorado at Colorado ... Zarand, //Iran, Sheldon Solomon, professor, Psychology, Skidmore College, ... University of Arizona, Tuscon. , In ... were questioned and were found that thoughts of ...
... practice followed is to begin immunizations of babies at two ... not achieve// the desired purpose, due to the incapacity of ... the vaccines. Now, according to a new study conducted by ... response in newborns, with a certain type of molecule present ...
... Health Organization (WHO) is in the process of updating the ... the new one, which will present// the rates at which ... form. ,The 20-year old charts are said to ... revision is based on growth data from breast-fed babies who ...
... of two decades ago still holds more than a third ... here still continues// to cause cancer in children according to ... ,According to official measurements published in the report at least ... for centuries as a result of the disaster. ...
Cached Medicine News:Health News:Depression Accompanies Heart Attacks in Younger Women 2
... intravascular catheters provide a simple, efficient ... pressures in the heart or cardiovascular ... are ideal for high fidelity pressure ... from 2 to 7 French and ...
... These dual pressure sensor ... sampling/slow-speed injection, slow-speed injection/guide wire, ... model SPC-784A for high-speed injection ... side openings and an open-end ...
... These dual pressure sensor catheters ... injection, slow-speed injection/guide wire, or ... SPC-784A for high-speed injection has ... openings and an open-end pigtail ...
... Dual Pressure Sensor Intravascular Mikro-Tip ... a line of dual pressure sensor ... measurements. These catheters are suitable for ... between chambers, or across a vascular ...
Medicine Products: